Synergistic pharmaceutical combination for the treatment of cancer

1. A method of treating a subject in need of treatment for pancreatic cancer, comprising:

administering:

a therapeutically effective amount of a cytotoxic antineoplastic agent, wherein the cytotoxic antineoplastic agent is gemcitabine or a pharmaceutically acceptable salt thereof; in combination with

a therapeutically effective amount of a CDK inhibitor or an enantiomer or a pharmaceutically acceptable salt thereof;

wherein said CDK inhibitor is represented by the formula:

wherein the cytotoxic antineoplastic agent is administered prior to the CDK inhibitor.

2. The method of claim 1 ;

wherein the combination exhibits therapeutic synergy.

3. The method of claim 1 ;

wherein the CDK inhibitor represented by compound of formula I is (+)-trans-2-(2-Chloro-phenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-chromen-4-one or its pharmaceutically acceptable salt.

4. The method of claim 1 ;

wherein the administration of the combination results in a synergistic increase in apoptosis.

5. The method of claim 1 ;

wherein the CDK inhibitor is a compound of formula I wherein the phenyl group is substituted by 1, 2, or 3 identical or different substituents selected from:

halogen selected from chlorine, bromine, fluorine, and iodine; and

C 1 -C 4 alkyl and trifluoromethyl.

6. The method of claim 5 ;

wherein the CDK inhibitor is a compound of formula I wherein the phenyl group is substituted by 1, 2, or 3 halogens selected from chlorine, bromine, fluorine, and iodine.

7. The method of claim 6 ;

wherein the CDK inhibitor is a compound of formula I wherein the phenyl group is substituted by chlorine.